drugset / Trial / NCT01241214

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214

Phase 2 Completed 579 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.

Timeline

Start
2010-11
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified
Subject Setipiprant Small molecule 100 mg Oral
Subject Setipiprant Small molecule 1000 mg Oral